Abstract 4368937: Rationale and Design of A Pragmatic Clinical Trial of the WE BEAT Well-Being Education Program in Adolescent Congenital Heart Disease: A Pediatric Heart Network (PHN) Study

M Melissa Cousino K Kurt Schumacher J Jessica Teng (Carelon Research, Newton, Massachusetts, United States) V Victor Zak (Carelon Research, Newton, Massachusetts, United States) A Adriana Batazzi (University of Michigan, Ann Arbor, Michigan, United States) L Louis Bezold (University of Kentucky, Lexington, Kentucky, United States) E Emily Bucholz (University of Colorado Denver, Aurora, Colorado, United States) K Kristin Burns (National Institutes of Health, Bethesda, Maryland, United States) P Paul Crister (Cincinatti Children's, Cincinatti, Ohio, United States) S Sarah de Ferranti (Harvard Medical School, Boston, Massachusetts, United States) A Amy Fung (CHILDRENS HOSPITAL COLORADO, Aurora, Colorado, United States) E Eric Graham (Medical University of South Carolina, Charleston, South Carolina, United States) S Sarah Kelly (Childrens Hospital Colorado, Aurora, Colorado, United States) L Lazaros Kochilas (Children’s Healthcare of Atlanta, GA (D.S., A.G.B., F.R.S., M.E.O., L.K.).) L Lauren Lorenzi Quigley (UMPC, Pittsburgh, Pennsylvania, United States) L Lindsay May (University of Utah, Salt Lake City, Utah, United States) J Julie Miller (Carelon Research, Newton, Massachusetts, United States) M Marion Ybarra (Washington University, St. Louis, Missouri, United States) M Mark Russell (Department of Pediatrics and Communicable Diseases, University of Michigan) M Marc Richmond (COLUMBIA UNIVERSITY MSCHONY, New York, New York, United States) S Shelley Miyamoto (Childrens Hospital Colorado, Aurora, Colorado, United States)

Abstract

Background: Adolescents with moderate and severe congenital heart disease (CHD) experience considerable risk of mental health comorbidities. Youth with CHD have 5-7 times greater odds of anxiety or depression than children without CHD. Psychological health is important to cardiac health, but there have been few CHD-specific psychological interventions. This PHN study will evaluate the effectiveness of a resilience and well-being-focused telemedicine intervention in adolescents with CHD and provide one of the largest linkages of self-reported psychosocial data with cardiac clinical outcomes. Research Questions: The WE BEAT CHD Study aims to: 1) evaluate the effectiveness of the 5-week WE BEAT telemedicine intervention compared to usual care on self-reported resiliency and psychosocial outcomes including depression, anxiety, and quality of life, 2) determine associations between psychosocial survey data and cardiac outcomes including composite event score, heart failure, and metabolic health, and 3) establish a biorepository to associate psychosocial data with stress-related biomarkers, including stress cortisol, inflammatory biomarkers, and epigenetic aging. Approach: In this 2-arm, 2-staged stratified randomized, parallel, multi-center pragmatic trial (Figure 1), we seek to recruit 390 English or Spanish speaking 12-17-year-olds with moderately or severely complex CHD across ~15 PHN core and auxiliary sites. The intervention arm will include 300 participants and half will be randomized to complete a booster session. Study design was informed by a successful pilot study, patient/family input, and pragmatic clinical trial design. Five 45-minute intervention sessions and study surveys completed at baseline, 5, 18 and 30 weeks will be done remotely via video conferencing and a study mobile app. Home collection of biospecimen samples will be available. Study duration is estimated to be 5 years. Results: The primary outcome will be change in participant self-reported resiliency as measured by the Connor-Davidson Resilience Scale© from baseline to Week 5, with secondary endpoints of change in resiliency from baseline to Weeks 18 and 30. Conclusion: This study addresses the need for promotive mental-health-focused interventions for adolescents with CHD. The pragmatic trial design intends to bolster successful recruitment and ease of translation to clinical practice. Secondary aims position the trial for mechanistic investigations and future ancillary studies.

Article Details

Journal Circulation
Volume / Issue Vol. 152, Issue Suppl_3
Published November 04, 2025
ISSN 0009-7322
Publisher Lippincott Williams & Wilkins

Journal Info

Circulation

Lippincott Williams & Wilkins

ISSN: 0009-7322 Health Sciences

Authors (21)

M

Melissa Cousino

K

Kurt Schumacher

J

Jessica Teng

Carelon Research, Newton, Massachusetts, United States

V

Victor Zak

Carelon Research, Newton, Massachusetts, United States

A

Adriana Batazzi

University of Michigan, Ann Arbor, Michigan, United States

L

Louis Bezold

University of Kentucky, Lexington, Kentucky, United States

E

Emily Bucholz

University of Colorado Denver, Aurora, Colorado, United States

K

Kristin Burns

National Institutes of Health, Bethesda, Maryland, United States

P

Paul Crister

Cincinatti Children's, Cincinatti, Ohio, United States

S

Sarah de Ferranti

Harvard Medical School, Boston, Massachusetts, United States

A

Amy Fung

CHILDRENS HOSPITAL COLORADO, Aurora, Colorado, United States

E

Eric Graham

Medical University of South Carolina, Charleston, South Carolina, United States

S

Sarah Kelly

Childrens Hospital Colorado, Aurora, Colorado, United States

L

Lazaros Kochilas

Children’s Healthcare of Atlanta, GA (D.S., A.G.B., F.R.S., M.E.O., L.K.).

L

Lauren Lorenzi Quigley

UMPC, Pittsburgh, Pennsylvania, United States

L

Lindsay May

University of Utah, Salt Lake City, Utah, United States

J

Julie Miller

Carelon Research, Newton, Massachusetts, United States

M

Marion Ybarra

Washington University, St. Louis, Missouri, United States

M

Mark Russell

Department of Pediatrics and Communicable Diseases, University of Michigan

M

Marc Richmond

COLUMBIA UNIVERSITY MSCHONY, New York, New York, United States

S

Shelley Miyamoto

Childrens Hospital Colorado, Aurora, Colorado, United States